Concerns that tumors may grow faster after the anticancer drug sunitinib is discontinued were raised by studies on animals. Despite this oncologists and physicists who collaborated to analyze data from the largest study of patients with kidney cancer convincingly demonstrate that such tumor acceleration does not occur in humans. The findings, publishing online on February 7th in the Cell Press journal iCell Reports/i, suggest that sunitinib does not cause lingering risks ...Sunday, 10 February 2013
Anticancer Drug Does Not Accelerate Tumor Growth After Treatment Ends: Findings
Concerns that tumors may grow faster after the anticancer drug sunitinib is discontinued were raised by studies on animals. Despite this oncologists and physicists who collaborated to analyze data from the largest study of patients with kidney cancer convincingly demonstrate that such tumor acceleration does not occur in humans. The findings, publishing online on February 7th in the Cell Press journal iCell Reports/i, suggest that sunitinib does not cause lingering risks ...
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment